Donor and transplant recipient demographic and clinical characteristics
| . | All (n = 253) . | CR1 (n = 183) . | CR2 (n = 70) . | P* . |
|---|---|---|---|---|
| Donor type, n (%) | NS | |||
| Related | 83 (32.8%) | 62 (33.9%) | 21 (30.0%) | |
| Unrelated | 170 (67.2%) | 121 (66.1%) | 49 (70.0%) | |
| Median donor age (range), y | 38.7 (5.7-77.8) | 39.1 (5.7-67.4) | 37.6 (10.6-77.8) | NS |
| Donor gender, n (%) | NS | |||
| Male | 125 (49.4%) | 96 (52.5%) | 29 (41.4%) | |
| Female | 109 (43.1%) | 72 (39.3%) | 37 (52.9%) | |
| Missing | 19 (7.5%) | 15 (8.2%) | 4 (5.7%) | |
| Patient/donor gender, n (%) | NS | |||
| Male/male | 66 (26.1%) | 49 (26.8%) | 17 (24.3%) | |
| Female/female | 56 (22.1%) | 40 (21.9%) | 16 (22.9%) | |
| Male/female | 53 (21.0%) | 32 (17.5%) | 21 (30.0%) | |
| Female/male | 59 (23.3%) | 47 (25.7%) | 12 (17.1%) | |
| Missing | 19 (7.5%) | 15 (8.2%) | 4 (5.7%) | |
| Conditioning regimen, n (%) | .001 | |||
| Bu/Cy ± ATG or CAMP | 65 (25.7%) | 57 (31.2%) | 8 (11.4%) | |
| Bu/Flu ± ATG | 34 (13.4%) | 24 (13.1%) | 10 (14.3%) | |
| H-TBI/Cy or H-TBI/TEPA/Flu | 72 (28.6%) | 48 (26.2%) | 24 (34.3%) | |
| Treo/Flu ± L-TBI | 68 (26.9%) | 49 (26.8%) | 19 (27.1%) | |
| Flu/radiolabeled Ab/L-TBI | 14 (5.5%) | 5 (2.7%) | 9 (12.9%) | |
| Source of stem cells, n (%) | NS | |||
| PBSC | 136 (53.8%) | 99 (54.1%) | 37 (52.9%) | |
| BM | 75 (29.6%) | 56 (30.6%) | 19 (27.1%) | |
| Cord Blood | 42 (16.6%) | 28 (15.3%) | 14 (20.0%) | |
| GVHD prophylaxis | NS | |||
| Calcineurin inhibitor + methotrexate | 170 (67.2%) | 129 (70.5%) | 41 (58.6%) | |
| Calcineurin inhibitor + MMF | 56 (22.1%) | 33 (18.0%) | 23 (32.9%) | |
| Cytoxan | 23 (9.1%) | 17 (9.3%) | 6 (8.6%) | |
| Other | 4 (1.6%) | 4 (2.2%) | 0 (0%) |
| . | All (n = 253) . | CR1 (n = 183) . | CR2 (n = 70) . | P* . |
|---|---|---|---|---|
| Donor type, n (%) | NS | |||
| Related | 83 (32.8%) | 62 (33.9%) | 21 (30.0%) | |
| Unrelated | 170 (67.2%) | 121 (66.1%) | 49 (70.0%) | |
| Median donor age (range), y | 38.7 (5.7-77.8) | 39.1 (5.7-67.4) | 37.6 (10.6-77.8) | NS |
| Donor gender, n (%) | NS | |||
| Male | 125 (49.4%) | 96 (52.5%) | 29 (41.4%) | |
| Female | 109 (43.1%) | 72 (39.3%) | 37 (52.9%) | |
| Missing | 19 (7.5%) | 15 (8.2%) | 4 (5.7%) | |
| Patient/donor gender, n (%) | NS | |||
| Male/male | 66 (26.1%) | 49 (26.8%) | 17 (24.3%) | |
| Female/female | 56 (22.1%) | 40 (21.9%) | 16 (22.9%) | |
| Male/female | 53 (21.0%) | 32 (17.5%) | 21 (30.0%) | |
| Female/male | 59 (23.3%) | 47 (25.7%) | 12 (17.1%) | |
| Missing | 19 (7.5%) | 15 (8.2%) | 4 (5.7%) | |
| Conditioning regimen, n (%) | .001 | |||
| Bu/Cy ± ATG or CAMP | 65 (25.7%) | 57 (31.2%) | 8 (11.4%) | |
| Bu/Flu ± ATG | 34 (13.4%) | 24 (13.1%) | 10 (14.3%) | |
| H-TBI/Cy or H-TBI/TEPA/Flu | 72 (28.6%) | 48 (26.2%) | 24 (34.3%) | |
| Treo/Flu ± L-TBI | 68 (26.9%) | 49 (26.8%) | 19 (27.1%) | |
| Flu/radiolabeled Ab/L-TBI | 14 (5.5%) | 5 (2.7%) | 9 (12.9%) | |
| Source of stem cells, n (%) | NS | |||
| PBSC | 136 (53.8%) | 99 (54.1%) | 37 (52.9%) | |
| BM | 75 (29.6%) | 56 (30.6%) | 19 (27.1%) | |
| Cord Blood | 42 (16.6%) | 28 (15.3%) | 14 (20.0%) | |
| GVHD prophylaxis | NS | |||
| Calcineurin inhibitor + methotrexate | 170 (67.2%) | 129 (70.5%) | 41 (58.6%) | |
| Calcineurin inhibitor + MMF | 56 (22.1%) | 33 (18.0%) | 23 (32.9%) | |
| Cytoxan | 23 (9.1%) | 17 (9.3%) | 6 (8.6%) | |
| Other | 4 (1.6%) | 4 (2.2%) | 0 (0%) |
Ab, antibody; ATG, antithymocyte globulin; BM, bone marrow; Bu, busulfan; CAMP, campath; Cy, cytoxan; Flu, fludarabine; H-TBI, high-dose TBI; L-TBI, low-dose TBI; MMF, mycophenolate mofetil; NS, not significant; PBSC, peripheral blood stem cells; TEPA, thiotepa.
For the comparison CR1 vs CR2.